The secondary myelofibrosis therapeutics market is projected to reach USD 2.25 billion by 2034, growing from USD 1.32 billion in 2025, at a CAGR of 6.1% during the forecast period from 2025 to 2034.
Secondary Myelofibrosis Therapeutics Market Statical Scope
| Reports Attributes | Statistics |
| Market Size in 2024 | USD 1.25 Billion |
| Market Size in 2025 | USD 1.32 Billion |
| Market Size in 2034 | USD 2.25 Billion |
| CAGR | 6.1% |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
Secondary Myelofibrosis Therapeutics Market Share, By Region, 2024 (%)
| Region | Shares (2024) |
| North America | 45% |
| Asia Pacific | 20% |
| Europe | 25% |
| Latin America | 6% |
| Middle East and Africa | 4% |
Reasons:
- North America (45%): Largest share due to advanced healthcare infrastructure and drug availability.
- Europe (25%): Strong adoption supported by reimbursement and access.
- Asia-Pacific (20%): Rising demand due to large patient base and improving facilities.
- Latin America (6%): Smaller share due to limited specialized care.
- Middle East & Africa (4%): Constrained by affordability and access issues.
Secondary Myelofibrosis Therapeutics Market Share, By Type, 2024 (%)
| Type | Shares (2024) |
| Targeted Drugs | 60% |
| Chemotherapy | 30% |
| Others | 10% |
Reasons:
- Targeted Drugs (60%): High adoption due to clinical benefits, precision-targeted approach, and increasing physician preference.
- Chemotherapy (30%): Still widely used but gradually being replaced by targeted options.
- Others (10%): Supportive care and experimental treatments, with limited market presence.
Secondary Myelofibrosis Therapeutics Market Share, By Application, 2024 (%)
| Applications | Shares (2024) |
| Hospitals | 70% |
| Ambulatory Surgical Centers | 20% |
| Others | 10% |
Reasons:
- Hospitals (70%): Primary treatment centers, equipped for complex therapies and infusion-based regimens.
- Ambulatory Surgical Centers (20%): Growing due to outpatient care convenience and lower cost.
- Others (10%): Includes specialty clinics, niche adoption.
Secondary Myelofibrosis Therapeutics Market Companies
- CTI BioPharma Corp
- Incyte Corporation
- Bristol-Myers Squibb Company
- Amneal Pharmaceuticals, Inc.
- AbbVie Inc.
- GlaxoSmithKline plc (GSK)
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- Ajax Therapeutics
Secondary Myelofibrosis Therapeutics Market Segmentations
By Type
- Targeted Drugs
- Chemotherapy
- Others
By Application
- Hospitals
- Ambulatory Surgical Centers
- Others
By Region
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East and Africa
Tables & Figures
By_Type
| Subsegment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Targeted Drugs | 0.75 | 0.81 | 0.87 | 0.93 | 1.00 | 1.08 | 1.16 | 1.24 | 1.33 | 1.43 | 1.54 | ||
| Chemotherapy | 0.38 | 0.39 | 0.41 | 0.42 | 0.44 | 0.45 | 0.47 | 0.49 | 0.51 | 0.52 | 0.54 | ||
| Others | 0.13 | 0.13 | 0.14 | 0.14 | 0.15 | 0.15 | 0.16 | 0.16 | 0.17 | 0.17 | 0.18 |
By_Application
| Subsegment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | 0.88 | 0.92 | 0.97 | 1.02 | 1.08 | 1.13 | 1.19 | 1.26 | 1.32 | 1.40 | 1.47 | ||
| Ambulatory Surgical Centers | 0.25 | 0.27 | 0.30 | 0.32 | 0.35 | 0.38 | 0.41 | 0.44 | 0.48 | 0.52 | 0.56 | ||
| Others | 0.13 | 0.13 | 0.14 | 0.15 | 0.16 | 0.17 | 0.18 | 0.19 | 0.20 | 0.21 | 0.23 |
By_Region
| Subsegment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | 0.56 | 0.59 | 0.62 | 0.66 | 0.69 | 0.73 | 0.77 | 0.81 | 0.86 | 0.90 | 0.95 | ||
| Europe | 0.31 | 0.33 | 0.35 | 0.36 | 0.38 | 0.40 | 0.42 | 0.45 | 0.47 | 0.49 | 0.52 | ||
| Asia-Pacific | 0.25 | 0.27 | 0.30 | 0.33 | 0.35 | 0.39 | 0.42 | 0.46 | 0.50 | 0.54 | 0.59 | ||
| Latin America | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | ||
| Middle East & Africa | 0.05 | 0.05 | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | 0.08 | 0.09 | 0.09 |
List of Figures & Tables
List of Tables (2024 Shares)
- Table 1: Market Segmentation by Type (2024)
- Targeted Drugs: 60%
- Chemotherapy: 30%
- Others: 10%
- Table 2: Market Segmentation by Application (2024)
- Hospitals: 70%
- Ambulatory Surgical Centers: 20%
- Others: 10%
- Table 3: Market Segmentation by Region (2024)
- North America: 45%
- Europe: 25%
- Asia-Pacific: 20%
- Latin America: 6%
- Middle East & Africa: 4%
List of Figures (2024 Shares)
- Figure 1: Share of Targeted Drugs, Chemotherapy, and Others in 2024
- Targeted Drugs: 60%
- Chemotherapy: 30%
- Others: 10%
- Figure 2: Application-wise Market Distribution in 2024
- Hospitals: 70%
- Ambulatory Surgical Centers: 20%
- Others: 10%
- Figure 3: Regional Market Distribution in 2024
- North America: 45%
- Europe: 25%
- Asia-Pacific: 20%
- Latin America: 6%
- Middle East & Africa: 4%
Frequently Asked Questions
The global secondary myelofibrosis therapeutics market was valued at USD 1.25 billion in 2024 and is projected to grow to USD 1.32 billion in 2025.
The market is expected to reach USD 2.25 billion by 2034, growing at a CAGR of 6.1% from 2025 to 2034.
North America holds 45% largest share due to advanced healthcare infrastructure, easy access to drugs, and higher adoption of targeted therapies.
Targeted drugs are growing because they offer precision therapy, clinical benefits, and higher physician preference, making them more effective than traditional chemotherapy.
The market in Middle East & Africa is constrained due to limited access to specialized care, affordability issues, and underdeveloped healthcare infrastructure.
Hospitals remain the dominant treatment setting (70%) due to complex therapies, but ambulatory surgical centers are growing as patients and providers prefer cost-effective and convenient outpatient treatments.
The forecast period is from 2025 to 2034, during which the market is expected to maintain a CAGR of 6.1%.
Make Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Published By
Kesiya Chacko
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
Our Client
Secondary Myelofibrosis Therapeutics Market to Reach USD 2.25 Billion by 2034
The secondary myelofibrosis therapeutics market is anticipated to grow from USD 1.25 billion in 2024 to USD 2.25 billion by 2034, achieving a CAGR of 6.1%.
